EXECUTIVE SUMMARY

Plasmology4® is pioneering a new and innovative field called Plasma Medicine, which is the coalescence of plasma physics, life sciences, and clinical medicine to facilitate the use of "cold plasma" technology for healthcare applications. The Company has developed a novel medical device that kills bacteria in wounds, including multidrug-resistant bacteria, on contact. Plasmas, or ionized gasses, are referred to as the 4th state of matter – hence the brand name Plaz4®. By combining high voltage electricity with a non-combustible gas, a glowing gas plasma is generated and delivered to wound tissues where it destroys pathogens. While highly energized, Plaz4® is completely cool to the touch and will not heat up tissues. Plaz4® has demonstrated the ability to destroy a broad spectrum of pathogens in a variety of pre–clinical studies. Moreover, the potential impact of the technology to improve patient outcomes was recently recognized by the Food and Drug Administration when Plaz4® technology was granted a designation into the Breakthrough Devices Program [Press Release].

Plasmology4® has created a strong and valuable patent portfolio with 38 issued United States and International patents, several patents pending, and dozens of additional concepts under development. The Company's executive management team and Scientific Advisory Board are seasoned professionals and Key Opinion Leaders in the areas of biomedical device product development, intellectual property protection, plasma science and engineering, biomedical research, and healthcare systems and delivery.

Plasmology4 was awarded a federal grant under the Therapeutic Discovery Project Program. This program provided grants to small companies with a promising and important therapeutic technology. The Company was also nominated by the Arizona Technology Council as one of the Best Innovative Startup Companies in Arizona.

*Plaz4® Technology is under review by the FDA and is not currently approved for use in humans.